BioCentury
ARTICLE | Financial News

NPS reports first Gattex sales

May 10, 2013 1:12 AM UTC

NPS Pharmaceuticals Inc. (NASDAQ:NPSP) reported 1Q13 earnings on Thursday, including $654,000 in the first sales of Gattex teduglutide, which the company launched in the U.S. in February to treat short bowel syndrome (SBS). NPS said that as of May 3, it has recorded 160 prescriptions, with 42 patients on Gattex. The drug has a U.S. list price of $295,000 annually.

On a conference call to discuss its earnings, NPS said it is still negotiating European reimbursement for teduglutide, which was approved in Europe last August under the name Revestive. The company said it will provide an update on the process in August and reiterated that it still hopes to have 200-300 patients on the analog of glucagon-like peptide-2 (GLP-2) by year end (see BioCentury, Jan. 14). ...